12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Orencia abatacept regulatory update

The U.K.'s NICE issued final guidance recommending IV Orencia abatacept from Bristol-Myers in combination with methotrexate to treat rheumatoid arthritis in adults whose disease has responded inadequately to 2 DMARDs. The guidance is in line with a...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >